Fox Chase Clinical Epidemiology and Validation Center

早期检测研究网络（EDRN）的总体目标是：a)确定癌症风险、早期检测、分子诊断和早期癌症预后的生物标志物；b)协调生物标志物研究和治疗策略，以降低癌症发病率和死亡率。作为临床验证中心（CVC），福克斯蔡斯癌症中心（FCCC）将：1)维持FCCC生物标志物验证研究者的多学科团队；2)遵守EDRN合作协议的条款和条件，包括数据共享；3)与EDRN生物标志物开发实验室（bdl）、生物标志物参考实验室（BRLs）、CVCs和数据管理与协调中心（DMCC）合作；4)参加EDRN指导委员会和科学会议和活动以及EDRN乳腺癌/卵巢癌联合小组；5)收集、储存和分发组织、血清和DNA，用于发现和验证生物标志物的研究，特别是来自有乳腺癌和卵巢癌风险的妇女；6)与盖辛格医学中心合作开展基于人群的生物标志物研究验证研究。fcc - edrn - cvc提出了一项研究人员发起的蛋白质组学和DNA甲基化II期生物标志物验证研究项目，该项目针对有浸润性癌症风险的良性乳腺疾病（BBD）女性。这项研究利用了过去五年EDRN资助期间收集的生物样本。研究目的：研究1，BBD候选蛋白质组生物学标志物的验证。目的1，验证蛋白生物标志物可鉴别癌前病变；目的2，在一组注释良好的临床标本中验证蛋白质组学生物标志物。研究2高甲基化标记的验证。目的1，验证基因甲基化对BBD风险分层的影响；目标2：开发一种基于血清的女性BBD检测方法。EDRN内外的众多合作者将利用fcc -EDRN- cvc大量带注释的乳腺和卵巢良性和癌症血清、DNA和组织样本。拟议的验证研究侧重于BBD，并研究相同病例中的蛋白质和DNA甲基化。FCCC EDRN-CVC将有助于将生物标志物研究转化为社区实践。

DESCRIPTION (provided by applicant): The overall goals of the Early Detection Research Network (EDRN) are to: a) identify biomarkers for cancer risk, early detection, molecular diagnostics, and prognosis of early cancer; and b) coordinate biomarker research and therapeutic strategies in order to reduce cancer morbidity and mortality. As a Clinical Validation Center (CVC), Fox Chase Cancer Center (FCCC) will: 1) maintain the FCCC multidisciplinary team of biomarker validation investigators; 2) comply with terms and conditions of the EDRN cooperative agreement including data sharing; 3) partner with EDRN Biomarker Development Labs (BDLs), Biomarker Reference Labs (BRLs), CVCs, and the Data Management and Coordination Center (DMCC); 4) participate in EDRN Steering Committee and Scientific meetings and activities and the EDRN Breast/Ovarian Cancer Consortium Group; 5) collect, store and distribute tissue, sera, and DNA for biomarker discovery and validation research especially from women at risk for breast and ovarian cancer; 6) partner with Geisinger Medical Center to develop population-based biomarker research validation studies. FCCC-EDRN-CVC proposes an investigator-initiated proteomic and DNA methylation phase II biomarker validation research project in women with benign breast disease (BBD) who are at risk for invasive cancer. This research utilizes biosamples collected during the past five years of EDRN funding. The aims are as follows: Study 1, Validation of candidate proteomic biomarker in BBD. Aim 1, verify that protein biomarker can distinguish preca-ncer lesions; Aim 2, validate proteomic biomarker in a set of well annotated clinical specimens. Study 2 Validations of Hypermethylated Markers. Aim 1, verify gene methylation for risk stratification in BBD; Aim 2, develop a serum-based assay in women with BBD. Numerous collaborators in and outside EDRN will utilize the FCCC-EDRN-CVC large annotated collection of breast and ovarian benign and cancer sera, DNA, and tissue samples. The proposed validation study is focused on BBD and investigates protein and DNA methylation in the same cases. The FCCC EDRN-CVC will help to translate biomarker research to community practice.